Blood test could boost colorectal cancer screening rates

NCT ID NCT05987709

Completed Diagnosis Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether offering a simple blood test (GuardantSHIELD) could help more people complete colorectal cancer screening compared to usual care. Over 2,000 adults aged 45-75 who were overdue for screening took part. The main goal was to see if more people got screened within 3 months when offered the blood test.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GuardantSHIELD Blood Test
What this could lead to: If successful, this blood test could offer a simpler, less invasive option to encourage more people to get screened for colorectal cancer.
What could go wrong: This is a completed study comparing screening completion rates, not a treatment trial. The blood test may not detect all cancers and abnormal results still require a follow-up colonoscopy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER

Contacts and locations

Show contact details

Locations

Kaiser Permanente Northwest

Portland, Oregon, 97227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.